Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse
暂无分享,去创建一个
P. Arese | A. Bottini | L. Dogliotti | E. De Fabiani | F. Nuzzo | A. de Matteis | M. Massobrio | M. Donadio | M. Tampellini | A. Berruti | G. Gorzegno | A. Farris | A. Durando | M. Sarobba | R. Bitossi | F. Castiglione | G. Moro | E. Manzin | G. Bonazzi
[1] M. McGuckin,et al. MUC1: Antibodies and Immunoassays , 2001, Tumor Biology.
[2] K. Nustad,et al. New Immunoassays for MUC1 in Breast Cancer , 2001, Tumor Biology.
[3] Olle Nilsson,et al. Automated Immunofluorometric Assay for MUC1 , 2001, Tumor Biology.
[4] P. Kenemans,et al. Quantification of MUC1 in breast cancer patients. A method comparison study. , 1999, European journal of obstetrics, gynecology, and reproductive biology.
[5] M. Duffy,et al. Preoperative CA 15‐3 concentrations predict outcome of patients with breast carcinoma , 1998, Cancer.
[6] R. Molina,et al. Use of blood tumour markers in the detection of recurrent breast cancer , 1998 .
[7] F. Real,et al. MUC6 expression in breast tissues and cultured cells: Abnormal expression in tumors and regulation by steroid hormones , 1998, International journal of cancer.
[8] M. McGuckin,et al. Progesterone stimulates production and secretion of MUC1 epithelial mucin in steroid-responsive breast cancer cell lines. , 1998, International journal of oncology.
[9] P. Zola,et al. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study , 1998, Cancer Chemotherapy and Pharmacology.
[10] O. Nilsson,et al. Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin , 1997, Tumor Biology.
[11] E. Seregni,et al. Mucinous Markers in Breast Cancer , 1997, Tumori.
[12] M. Brizzi,et al. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[13] L. Dogliotti,et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. , 1997, British Journal of Cancer.
[14] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[15] A. Fazleabas,et al. Mucin (Muc-1) expression is differentially regulated in uterine luminal and glandular epithelia of the baboon (Papio anubis). , 1996, Biology of reproduction.
[16] Z. Marom,et al. Mucin genes are regulated by estrogen and dexamethasone. , 1995, Biochemical and biophysical research communications.
[17] S. Dey,et al. Expression and steroid hormonal control of Muc-1 in the mouse uterus. , 1995, Endocrinology.
[18] Walsh,et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. , 1995, Human pathology.
[19] A Pilo,et al. Comparison of Immunoassays for Tumor Markers CA 19-9, CA 15-3 and CA 125: Data from an International Quality Assessment Scheme , 1995, Tumori.
[20] M. Gion,et al. Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] L. Dogliotti,et al. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. , 1994, European journal of cancer.
[22] W. Jäger. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. , 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[23] M. Gion,et al. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. , 1991, British Journal of Cancer.
[24] A. Papadimitriou,et al. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Á. Ruibal,et al. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease , 1989, Cancer.
[26] A. Howell,et al. The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment. , 1989, European journal of cancer & clinical oncology.
[27] B. Takács,et al. Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes. , 1988, Cancer research.
[28] P. Bruning,et al. Comparison of circulating mam‐6 and cea levels and correlation with the estrogen receptor in patients with breast cancer , 1987, International journal of cancer.
[29] G. Hortobagyi,et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.